Clinical Trials Logo

Mycoses clinical trials

View clinical trials related to Mycoses.

Filter by:

NCT ID: NCT05368948 Not yet recruiting - Fungal Infection Clinical Trials

The Assessment of Antimicrobial Peptides Against Fungal Infection

Start date: December 2022
Phase:
Study type: Observational

- Identification of different types of fungi. - Determine sensitivity the profile and the resistance pattern of the clinical isolates against antifungal. - Determine the antifungal effects of defensin, cathelicidin and histatins and their effects on biofilm formation and resistant isolates.

NCT ID: NCT05205902 Not yet recruiting - Mycosis Fungoides Clinical Trials

TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides

TOTEM-01
Start date: February 2022
Phase: Phase 3
Study type: Interventional

Primary cutaneous T-cell lymphomas are a group of peripheral T-cell lymphomas that primarily involve the skin. Mycosis fungoides (MF) is the most frequent subtype. Most patients with early-stage MF (i.e., patches and plaques of the skin without extracutaneous involvement) have a good prognosis but a subset of patients progress to incurable advanced-stage disease with an overall survival (OS) less than 5 years and an impaired quality of life. We have recently identified the tumor clone frequency in lesional skin (measured by high-throughput sequencing of the TCRB locus) as the most important prognostic factor of progression-free survival (PFS) and OS in a retrospective analysis on 210 patients with early-stage MF (p<0.001). Phototherapy is a standard therapeutic option in early-stage MF but fails to eradicate the tumor clone from the skin. Low-dose total-skin electron-beam therapy (LDTSEBT, 12 Gy over a 3-week period) has been shown to be safe and highly effective in MF with an 88% overall response rate and a better safety profile compared to standard-dose total-skin electron-beam therapy, in a pooled analysis from 3 phase II trials on 33 patients and a retrospective analysis of 12 patients treated with LDTSEBT. We hypothesize that the use of LDTSEBT is associated with a significantly higher 1-year PFS compared to conventional treatment with phototherapy. Our secondary hypotheses are that LDTSEBT is associated with a higher tumor T-cell clone eradication compared to phototherapy, and improves OS and quality of life in patients with skin-limited MF. The main objective of this study is therefore to prospectively determine if LDTSEBT is associated with a higher 1-year progression-free survival in patients with early-stage mycosis fungoides, compared to conventional treatment with phototherapy. The primary endpoint is PFS at 12 months after study inclusion.

NCT ID: NCT05106192 Not yet recruiting - Clinical trials for Non Hodgkin Lymphoma

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

NCT ID: NCT04728971 Not yet recruiting - Clinical trials for Liver Transplantation

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.

NCT ID: NCT04725942 Not yet recruiting - Clinical trials for Pulmonary Fungal Infection

Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients

Start date: January 2021
Phase:
Study type: Observational

This open, prospective, observational multicenter cohort study aims to evaluate the efficacy, safety as well as the effective serum concentration of Posaconazole for prevention of pulmonary fungal infections in patients with hematopoietic stem cell transplantation. The correlation of UGT1A4*3 genotype and Cmin of Posaconazole, as well as invasive fungal disease (IFD) breakthrough rates will be utilized to evaluate the efficacy while the safety of Posaconazole will be assessed by the overall incidence and severity of adverse events in patients.

NCT ID: NCT04684342 Not yet recruiting - Fungal Infection Clinical Trials

Fungal Infection in Patients in Intensive Care Units

Start date: January 2021
Phase: N/A
Study type: Interventional

Predictors of fungal infection in non-neutropenic patients in intensive care units and the aim of the study is To evaluate the frequency of fungal infection in non-neutropenic patients in Intensive Care Units. To evaluate the risk factors of fungal infection in these patients.

NCT ID: NCT04619147 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

Invasive Fungal Infections in Patients Following Stem Cell Transplant

Start date: January 2021
Phase:
Study type: Observational

This study will be a descriptive, retrospective evaluation and analysis of invasive fungal infections (IFI) conducted in patients who underwent allogeneic haematopoiectic stem cell transplant (aHSCT) in a single tertiary transplant centre, the Bone Marrow Transplant Clinical Service across Peter MacCallum Cancer Centre (PMCC) and Royal Melbourne Hospital (RMH), Victoria, Australia.

NCT ID: NCT04386031 Not yet recruiting - Clinical trials for Prevalence of Fungal Infection in Patients Undergoing Oral Cavity Surgery Without Treatment With Antifungal Drug

Fungal Infection After Oral Cavity Surgeries

Start date: June 1, 2020
Phase:
Study type: Observational

this prospective study we will examine the prevalence of fungal infection in patients undergoing oral cavity surgery without treatment with antifungal drug

NCT ID: NCT04215458 Not yet recruiting - Fungal Infection Clinical Trials

Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The pathogeneses of many inflammatory diseases are not completely understood, yet, dysregulation of the human microbiota is increasingly being investigated as a possible contributing factor. The human microbiota includes bacteria, archaea, viruses and fungi. In general, little is known about the fungal colonization in inflammatory skin diseases. This study aims to examine the prevalence of microbiome in skin and oral mucosa of a variety of patients and healthy volunteers visiting the Dermatological outpatient clinic. The study is designed as a case-control study comparing the incidence of colonization or infection in skin and oral mucosa of patients with different skin diseases and healthy volunteers. Patients with selected skin diseases, staff at Zealand University Hospital in Roskilde, relatives to staff and students with relation to the Dermatologic Department will be asked to fill out a short questionnaire and have swaps taken from oral mucosa, as well as skin scrapings and tape strips from lesional skin (only patients) and non-lesional skin (all).

NCT ID: NCT04041739 Not yet recruiting - Clinical trials for Diabetic Foot Osteomyelitis

Fungal Infection in Patients With Diabetic Foot Osteomyelitis

Start date: January 2020
Phase:
Study type: Observational

estimate the percentage of fungal infection in the pathogenesis of diabetic foot osteomyelitis and assess the outcome of patients with fungal diabetic foot osteomyelitis